PET–Computed Tomography and Precision Medicine in Pancreatic Adenocarcinoma and Pancreatic Neuroendocrine Tumors

Daniella F. Pinho; Rathan M. Subramaniam

doi:10.1016/j.cpet.2017.05.003

PET–Computed Tomography and Precision Medicine in Pancreatic Adenocarcinoma and Pancreatic Neuroendocrine Tumors

Daniella F. Pinho, Rathan M. Subramaniam

Research output: Contribution to journal › Review article

1 Scopus citations

Abstract

¹⁸F-FDG PET/CT has been described as an accurate tool for initial diagnosis of pancreatic adenocarcinoma. It differentiates benign from malignant causes; detects local and, especially, distant spread of disease; and is a very good predictor of patient prognosis. Pancreatic neuroendocrine tumors are rare tumors that originate from the islet cells of the pancreas. Currently, ⁶⁸Ga-DOTA-labeled somatostatin analogs are considered the best modality for detection of well-differentiated neuroendocrine tumors. ¹⁸F-FDG PET/CT has a role in patients with poorly differentiated tumors. Recent studies have demonstrated improved survival in patients with metastatic neuroendocrine tumors treated with radiolabeled somatostatin analogs.

Original language	English (US)
Pages (from-to)	407-421
Number of pages	15
Journal	PET Clinics
Volume	12
Issue number	4
DOIs	https://doi.org/10.1016/j.cpet.2017.05.003
Publication status	Published - Oct 1 2017

Fingerprint

Keywords

Pancreatic adenocarcinoma
Pancreatic cancer
Pancreatic neuroendocrine tumor
PET
PET/CT

ASJC Scopus subject areas

Radiation
Radiology Nuclear Medicine and imaging

Cite this

Pinho, D. F., & Subramaniam, R. M. (2017). PET–Computed Tomography and Precision Medicine in Pancreatic Adenocarcinoma and Pancreatic Neuroendocrine Tumors. PET Clinics, 12(4), 407-421. https://doi.org/10.1016/j.cpet.2017.05.003

@article{b22fb37ccfc549fcaf2f2542b0f81eee,

title = "PET–Computed Tomography and Precision Medicine in Pancreatic Adenocarcinoma and Pancreatic Neuroendocrine Tumors",

abstract = "18F-FDG PET/CT has been described as an accurate tool for initial diagnosis of pancreatic adenocarcinoma. It differentiates benign from malignant causes; detects local and, especially, distant spread of disease; and is a very good predictor of patient prognosis. Pancreatic neuroendocrine tumors are rare tumors that originate from the islet cells of the pancreas. Currently, 68Ga-DOTA-labeled somatostatin analogs are considered the best modality for detection of well-differentiated neuroendocrine tumors. 18F-FDG PET/CT has a role in patients with poorly differentiated tumors. Recent studies have demonstrated improved survival in patients with metastatic neuroendocrine tumors treated with radiolabeled somatostatin analogs.",

keywords = "Pancreatic adenocarcinoma, Pancreatic cancer, Pancreatic neuroendocrine tumor, PET, PET/CT",

author = "Pinho, {Daniella F.} and Subramaniam, {Rathan M.}",

year = "2017",

month = "10",

day = "1",

doi = "10.1016/j.cpet.2017.05.003",

language = "English (US)",

volume = "12",

pages = "407--421",

journal = "PET Clinics",

issn = "1556-8598",

publisher = "W.B. Saunders Ltd",

number = "4",

}

TY - JOUR

T1 - PET–Computed Tomography and Precision Medicine in Pancreatic Adenocarcinoma and Pancreatic Neuroendocrine Tumors

AU - Pinho, Daniella F.

AU - Subramaniam, Rathan M.

PY - 2017/10/1

Y1 - 2017/10/1

N2 - 18F-FDG PET/CT has been described as an accurate tool for initial diagnosis of pancreatic adenocarcinoma. It differentiates benign from malignant causes; detects local and, especially, distant spread of disease; and is a very good predictor of patient prognosis. Pancreatic neuroendocrine tumors are rare tumors that originate from the islet cells of the pancreas. Currently, 68Ga-DOTA-labeled somatostatin analogs are considered the best modality for detection of well-differentiated neuroendocrine tumors. 18F-FDG PET/CT has a role in patients with poorly differentiated tumors. Recent studies have demonstrated improved survival in patients with metastatic neuroendocrine tumors treated with radiolabeled somatostatin analogs.

AB - 18F-FDG PET/CT has been described as an accurate tool for initial diagnosis of pancreatic adenocarcinoma. It differentiates benign from malignant causes; detects local and, especially, distant spread of disease; and is a very good predictor of patient prognosis. Pancreatic neuroendocrine tumors are rare tumors that originate from the islet cells of the pancreas. Currently, 68Ga-DOTA-labeled somatostatin analogs are considered the best modality for detection of well-differentiated neuroendocrine tumors. 18F-FDG PET/CT has a role in patients with poorly differentiated tumors. Recent studies have demonstrated improved survival in patients with metastatic neuroendocrine tumors treated with radiolabeled somatostatin analogs.

KW - Pancreatic adenocarcinoma

KW - Pancreatic cancer

KW - Pancreatic neuroendocrine tumor

KW - PET

KW - PET/CT

UR - http://www.scopus.com/inward/record.url?scp=85023625779&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85023625779&partnerID=8YFLogxK

U2 - 10.1016/j.cpet.2017.05.003

DO - 10.1016/j.cpet.2017.05.003

M3 - Review article

C2 - 28867112

AN - SCOPUS:85023625779

VL - 12

SP - 407

EP - 421

JO - PET Clinics

JF - PET Clinics

SN - 1556-8598

IS - 4

ER -

Access to Document

10.1016/j.cpet.2017.05.003